Triaxone 1 gm Vial IV

Product Description:

• Antibiotic belongs to the third generation of cephalosporins used in the treatment of bacterial meningitis, acute otitis media, pneumonia, urinary tract infection and diabetic foot infection.

Indication & Usage:

• Acute Otitis Media: IM/IV: 1–2 g once daily × 3 days


• Pneumonia (inpatients, no P. aeruginosa risk): IV: 1–2 g once daily + other agents, minimum 5 days (oral step-down possible)


• Salmonella (Enteric fever): IV: 2 g every 12–24 h × 10–14 days


• COPD Exacerbation: IV: 1 g once daily × 5–7 days


• Diabetic Foot Infection: IV: 1–2 g once daily + other agents, usually 2–4 weeks


• Bacterial Meningitis: IV: 2 g every 12 h × 7–21 days


• STIs:


• Uncomplicated gonorrhea: IM: 500 mg single dose (1 g if ≥150 kg)


• Disseminated gonococcal infection: IV/IM: 1 g once daily


• Neurosyphilis: IM/IV: 1–2 g once daily × 10–14 days


• Complicated UTI:


• Inpatients: IV: 1 g once daily, total 5–14 days (oral switch possible)


• Outpatients: IV/IM: 1 g once, then oral therapy × 5–14 days


• Skin & Soft Tissue Infection: IV: 1–2 g once daily (in combination), duration varies


• Pediatric dosing: Refer to dosage & administration guidelines

Side Effects:

• Clostridioides difficile associated diarrhea, hemolytic anemia, anaphylaxis and Kernicterus has been reported in neonates. -Skin tightness, warm sensation at injection site, flushing, diaphoresis, pruritus, skin rash, nausea, vomiting, casts in urine, vaginitis, anemia, eosinophilia, hemolytic anemia, leukopenia, lymphocytopenia.


• neutropenia, prolonged prothrombin time, thrombocythemia, thrombocytopenia, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin, candidiasis, tenderness at injection site, chills, dizziness, headache, increased blood urea nitrogen, increased serum creatinine, palpitations, glycosuria, abdominal pain, choledocholithiasis.


• cholelithiasis, dyspepsia, flatulence, gallbladder sludge, pancreatitis, hematuria, agranulocytosis, basophilia, decreased prothrombin time, granulocytopenia, lymphocytosis, monocytosis, Jaundice, seizure, bronchospasm, epistaxis and hypersensitivity pneumonitis. Ceftriaxone-calcium precipitation occurs when co-administered with calcium intravenously.


• leading to fatal lung and kidney damage in premature and term neonates. Urinary sludge (hypercalciuria), nephrolithiasis, urolithiasis, and acute renal failure have been reported. Gallbladder sludge, cholelithiasis, and pseudolithiasis (choledocholithiasis), as well as subsequent pancreatitis, have also occurred. Most reports have occurred in pediatric patients; however, there are reports in adults.

Safety Advice

• For intravenous injection only. Should not be given to patients suffering from hypersensitivity to ceftriaxone.


• Rapid intravenous push injection over 5 minutes of a 2,000 mg dose resulted in tachycardia, restlessness, diaphoresis, and palpitations in an adult patient.


• Should not be given to premature hyperbilirubinemic neonates. May cause an increase in INR, especially in case of nutritionally deficient patients, prolonged treatment, hepatic or renal disease.


• Prolonged use may result in fungal or bacterial superinfection.


• Use with caution in patients with concurrent hepatic dysfunction and severe kidney disease.


• In case of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention.

Storage:

• Store at room temperature.